Holen Sie sich die Stockscreener-App
4.15
2.47%
0.10
Handel nachbörslich:
4.13
-0.02
-0.48%
Schlusskurs vom Vortag:
$4.05
Offen:
$4.13
24-Stunden-Volumen:
191.06K
Relative Volume:
1.26
Marktkapitalisierung:
$243.66M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-74.28M
KGV:
-3.4064
EPS:
-1.2183
Netto-Cashflow:
$-86.15M
1W Leistung:
+2.22%
1M Leistung:
+8.64%
6M Leistung:
-17.00%
1J Leistung:
-12.63%
1-Tages-Spanne:
$4.05
$4.17
1-Wochen-Bereich:
$3.96
$4.29
52-Wochen-Spanne:
$3.27
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.15 | 243.66M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2025-12-18 | Eingeleitet | BTIG Research | Buy |
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics Inc. (FHTX) Institutional Confidence - TradingKey
Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Foghorn Therapeutics Inc. (FHTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Investing News Network
Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event - Stock Titan
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO) - The Globe and Mail
Foghorn Therapeutics to Present at Three Investor Conferences in May - geneonline.com
Foghorn Therapeutics (FHTX) Rises 1.44% as Biotech Stock Tests Key Resistance at $4.43MESA MA - newsline.com
Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan
EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov
[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Foghorn Therapeutics (FHTX) Slides -1.68% as Selling Pressure Mounts 2026-05-14Wyckoff Accumulation - newsline.com
Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News
Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network
Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics Inc. (FHTX) reports Q1 loss, lags revenue estimates - MSN
Wedbush Reaffirms Their Buy Rating on Foghorn Therapeutics (FHTX) - The Globe and Mail
Wedbush Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update - Investing News Network
Number of shareholders of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline - TipRanks
Foghorn Therapeutics Inc. 1Q 2026: Revenue $3.3M, EPS $(0.29) — 10-Q Summary - TradingView
Foghorn says lead lung cancer trial stays on track, funded into 2028 - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) trims expenses, raises $50M in Q1 2026 - Stock Titan
Foghorn Therapeutics (Nasdaq: FHTX) details Q1 2026 results and oncology pipeline - Stock Titan
FMR LLC reports 11.6% ownership in Foghorn Therapeutics (NASDAQ: FHTX) - Stock Titan
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
The quiet positioning of Foghorn Therapeutics (FHTX) nobody discusses (Market Focus) 2026-05-06RVOL Spike - newsline.com
[ARS] Foghorn Therapeutics Inc. SEC Filing - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9%Time to Sell? - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating on AACR data By Investing.com - Investing.com Australia
Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Stifel reiterates Foghorn Therapeutics stock rating on AACR data - Investing.com
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):